A response rate of 33.3% (95% CI, 24.6%–43.1%) was observed.
The median duration of response was 7.7 months (95% CI, 4.9–10.8).
The main toxicity was neutropenia, and four deaths occurred during treatment.[61][Level of evidence C3] The FDA granted accelerated approval to sacituzumab govitecan for patients with metastatic TNBC after at least two previous lines of therapy.
A phase III randomized trial (ASCENT[NCT02574455]) confirmed the efficacy of sacituzumab govitecan in patients with metastatic TNBC that was relapsed or refractory to two or more previous chemotherapy regimens.
The trial randomly assigned 468 women without brain metastases to receive either sacituzumab govitecan or the physician's choice of single-agent chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine).